Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter W de Herder

Showing results (91-100 of 238) with videos related to

Pageof 24
Sort By:
Cancers|January 28, 2021
Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine TumoursAnela Blažević, Tessa Brabander, Wouter T Zandee, et al.
Trials|January 16, 2024
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NETSimron Singh, Diego Ferone, Jaume Capdevila, et al.
Endocrine Connections|May 25, 2016
Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors?Roxanne C S van Adrichem, Aart Jan van der Lely, Martin Huisman, et al.
Endocrine-Related Cancer|October 8, 2020
Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imagingJulie Refardt, Wouter T Zandee, Tessa Brabander, et al.
The Journal of Clinical Endocrinology and Metabolism|June 7, 2014
Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-upKimberly Kamp, Richard A Feelders, Roxanne C S van Adrichem, et al.
Seminars in Nuclear Medicine|February 2, 2010
Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumorsDik J Kwekkeboom, Wouter W de Herder, Casper H J van Eijck, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|March 15, 2016
Peptide receptor radionuclide therapy of neuroendocrine tumoursTessa Brabander, Jaap J M Teunissen, Casper H J Van Eijck, et al.
Cancer Research|January 7, 2006
IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitroGiovanni Vitale, Wouter W de Herder, Peter M van Koetsveld, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapyEric P Krenning, Roelf Valkema, Dik J Kwekkeboom, et al.
Neuroendocrinology|July 20, 2018
Identifying Prognostic Factors for Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumours: A Retrospective International Multicentre Cohort StudyPaula Jiménez-Fonseca, Sebastian Krug, Gianluca Tamagno, et al.
Pageof 24

Showing results (91-100 of 238) with videos related to

Sort By:
Pageof 24
Cancers|January 28, 2021
Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine TumoursAnela Blažević, Tessa Brabander, Wouter T Zandee, et al.
Trials|January 16, 2024
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NETSimron Singh, Diego Ferone, Jaume Capdevila, et al.
Endocrine Connections|May 25, 2016
Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors?Roxanne C S van Adrichem, Aart Jan van der Lely, Martin Huisman, et al.
Endocrine-Related Cancer|October 8, 2020
Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imagingJulie Refardt, Wouter T Zandee, Tessa Brabander, et al.
The Journal of Clinical Endocrinology and Metabolism|June 7, 2014
Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-upKimberly Kamp, Richard A Feelders, Roxanne C S van Adrichem, et al.
Seminars in Nuclear Medicine|February 2, 2010
Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumorsDik J Kwekkeboom, Wouter W de Herder, Casper H J van Eijck, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|March 15, 2016
Peptide receptor radionuclide therapy of neuroendocrine tumoursTessa Brabander, Jaap J M Teunissen, Casper H J Van Eijck, et al.
Cancer Research|January 7, 2006
IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitroGiovanni Vitale, Wouter W de Herder, Peter M van Koetsveld, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapyEric P Krenning, Roelf Valkema, Dik J Kwekkeboom, et al.
Neuroendocrinology|July 20, 2018
Identifying Prognostic Factors for Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumours: A Retrospective International Multicentre Cohort StudyPaula Jiménez-Fonseca, Sebastian Krug, Gianluca Tamagno, et al.
Pageof 24